Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Manhattan Associates Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Manhattan Associates Inc trades at $153.56 (market cap $9.37B). The key difference: Manhattan Associates Inc is far larger — about 2.1× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | MANH | |
|---|---|---|
Market Cap | $4.49B | $9.37B |
Sector | Health | Technology |
52-Week High | $28.06 | $227.94 |
52-Week Low | $20.06 | $120.88 |
Enterprise Value | $3.69B | $9.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
MANH trades at $153.81, up 1.83% today, with a bullish technical outlook supported by moving averages and strong support at $150. The company demonstrates robust profitability with a 19.68% net margin and has beaten earnings estimates for three consecutive quarters. However, valuation ratios appear elevated with a P/E of 43.1, while ongoing legal investigations pose sentiment risks.
The stock offers upside to the $192.80 consensus price target but faces headwinds from high valuation multiples and legal uncertainties. Earnings growth and cloud strategy execution remain key catalysts, though investors must weigh these against potential dilution from the fiduciary duty investigations highlighted repeatedly in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
